CalciMedica (CALC) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

1. 01the costs of operating as a public company
2. 02Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our proprietary platform or product candidates
3. 03Any acquisitions or strategic collaborations may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities or subject us to other risks
4. 04our inability to generate revenue from acquired products, product candidates, intellectual property rights, technologies, and/or businesses sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs
5. 05The terms of the 2025 LSA place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility
6. 06If we are unable to maintain our listing on Nasdaq, it could become more difficult to sell our common stock in the public market
7. 07market or exchange could reduce the liquidity of our common stock. If our common stock were to trade in the OTC market, an investor would find it more difficult to dispose of, or to obtain accurate quotations for the price of, the common stock

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

1. 08Our business is highly dependent on the success of our product candidates, in particular Auxora, and we may fail to develop Auxora successfully or be unable to obtain regulatory approval
2. 09clinical trials may not be successful. Any of these events could cause delays and interruptions in our clinical trials, which could adversely affect our business
3. 10disruptions at the FDA and other governmental agencies caused by funding or staffing shortages
4. 11We conducted a significant portion of our CARPO trial in India, and regulatory authorities may not accept data from such trial or any future clinical trials we conduct outside the United States or the applicable foreign jurisdiction
5. 12We depend on enrollment of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, results of operations and prospects could be adversely affected
6. 13clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies
7. 14Preliminary, interim and topline data from our clinical trials may change as more participant data becomes available, and are subject to audit and verification procedures that could result in material changes in the final data
8. 15causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk- benefit perspective or in which efficacy is more pronounced or durable
9. 16Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could seriously harm our business
10. 17We may seek various designations by the regulatory authorities for any product candidates that we develop, such as Fast Track designation or Breakthrough Therapy designation
11. 18We may seek orphan drug designation for our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity
12. 19Our product candidates must meet extensive regulatory requirements before they can be commercialized and any regulatory approval may contain limitations or conditions that require substantial additional development expenses or limit our ability to successfully commercialize our product candidates
13. 20To date, we have not submitted an NDA or other marketing authorization application to the FDA or similar drug approval submissions to comparable foreign regulatory authorities for any product candidates
14. 21the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators’ clinical data insufficient for approval
15. 22We will need to obtain FDA approval of any proposed product names, including Auxora, and any failure or delay associated with such approval may adversely affect our business
16. 23injunctions or the imposition of civil or criminal penalties
17. 24The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
18. 25We may not identify or discover other product candidates and may fail to capitalize on our proprietary platform or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success
19. 26a product candidate may not be accepted as safe and effective by patients, the medical community or third- party payors
20. 27Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop

Risks Related to Manufacturing, Commercialization and Reliance on Third Parties

1. 28We contract with third parties for the manufacturing and supply of certain goods and services for our product candidates for use in preclinical studies and clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity
2. 29Any approved product candidates may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success
3. 30We may not be able to successfully commercialize our product candidates due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably
4. 31new products when more established or lower cost therapeutic alternatives are already available or subsequently become available
5. 32neither experimental nor investigational
6. 33Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such product candidates outside of the United States, which would limit our ability to realize their full market potential

Risks Related to Our Industry and Business Operations

1. 34We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan
2. 35We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
3. 36improve our operational, financial and management controls, reporting systems and procedures
4. 37continue to improve our operational, financial and management controls, reports systems and procedures
5. 38We face substantial competition, which may result in others discovering, developing or commercializing product candidates more quickly or marketing them more successfully than us
6. 39in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical
7. 40We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans
8. 41and whether such a collaboration could be more attractive than the one with us for our product candidates. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators
9. 42Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products
10. 43a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings
11. 44We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters, terrorism or similar unforeseen events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
12. 45Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
13. 46Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
14. 47Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations
15. 48We are subject to applicable fraud and abuse, transparency, government price reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties
16. 49divert management’s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business
17. 50Our current or future employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading

Risks Related to Our Intellectual Property

1. 51countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidates in those countries
2. 52the patents of others may have an adverse effect on our business
3. 53Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
4. 54If we do not obtain patent term extension for Auxora, our business may be materially harmed
5. 55Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 56Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect Auxora
7. 57We may not be able to protect our intellectual property rights throughout the world
8. 58We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
9. 59We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses
10. 60Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery and development efforts
11. 61require us to enter into royalty or license agreements, which may not be available on commercially reasonable terms, or at all
12. 62additionally, generative artificial intelligence (AI) resources that are publicly available also present a risk that a company may inadvertently obtain, incorporate or use a third party's intellectual property
13. 63We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers
14. 64Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
15. 65If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
16. 66Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations
17. 67If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
18. 68Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business
19. 69Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations
20. 70The market price of our stock has been and may continue to be volatile, and you could lose all or part of your investment
21. 71period-to-period fluctuations in our financial results
22. 72Financial reporting obligations of being a public company in the United States are expensive and time-consuming, and our management needs to devote substantial time to compliance matters
23. 73The relative lack of public company experience of our management team may put us at a competitive disadvantage
24. 74Substantial future sales of shares of our common stock could adversely affect the market price of such shares
25. 75Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
26. 76We are a smaller reporting company. We cannot be certain whether the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors or otherwise limit our ability to raise additional funds
27. 77Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain
28. 78If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
29. 79Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
30. 80Our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees
31. 81Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations